NVIDIA CORPNVIDIA CORP

Institutional investor · Portfolio as of Q1 2024

SEC EDGAR SourceSEC Filings

Top Holdings4 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
ARMARM
ADR

ARM Holdings PLC Sponsored ADR

2M$245.1M73.7%$75.14+66.34%
2 qtrssince 2023-Q4
Unchanged
0

RECURSION PHARMACEUTICALS IN

7.7M$76.8M23.1%$9.86+1.12%
2 qtrssince 2023-Q4
Unchanged
0

SOUNDHOUND AI INC

1.7M$10.2M3.1%$2.12+177.83%
2 qtrssince 2023-Q4
Unchanged
0

NANO X IMAGING LTD

59,632$582,6050.2%$6.37+53.38%
2 qtrssince 2023-Q4
Unchanged
0
$332.7M
AUM
4
Positions
Q1 2024
Filing
Rating · 1.5
Quarterly Portfolio Change
Not enough history yet
Activity profile
$ moved · Q1'24
New0%Increased0%Decreased0%Exited100%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.0 quarters
<1Q0%1-4Q100%1-2Y0%2Y+0%

NVIDIA CORP manages $332.7M across 4 positions as of Q1 2024. Top holdings: ARM (73.7%), RXRX (23.1%), SOUN (3.1%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.

Q1 2024 Summary

Exited 1. No standout high-conviction moves this quarter. Portfolio: $333M across 4 positions.

Top holdings by portfolio weight

Total AUM$333M
ARM73.67%
RXRX23.09%
SOUN3.06%
NNOX0.18%
TSPH0.00%

Portfolio allocation by GICS sector

Sectors2
Technology76.73%
Healthcare23.27%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction45
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used